Author: Macchi M1, Belfiore MP2, Floridi C3, Serra N4, Belfiore G5, Carmignani L6, Grasso RF7, Mazza E8, Pusceddu C9, Brunese L10, Carrafiello G11
Affiliation: <sup>1</sup>Department of Radiology, Circolo e Fondazione Macchi Hospital, Insubria University, Varese, Italy.
<sup>2</sup>Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
<sup>3</sup>Radiology Department, Fatebenefratelli Hospital, Milan, Italy. chiara.floridi@gmail.com.
<sup>4</sup>Department of Radiology and Radiotherapy, University of Campania "Luigi Vanvitelli", Naples, Italy.
<sup>5</sup>Department of Radiology, Sant'Anna e San Sebastiano Hospital, Caserta, Italy.
<sup>6</sup>Interventional Radiology Unit, San Jacopo Hospital, Pistoia, Italy.
<sup>7</sup>Department of Diagnostic and Interventional Radiology, Campus Bio-Medico University, Rome, Italy.
<sup>8</sup>Interventional Radiology Unit, Careggi Hospital, Florence, Italy.
<sup>9</sup>Division of Interventional Radiology, Department of Oncological Radiology, Oncological Hospital "A. Businco", Cagliari, Italy.
<sup>10</sup>Department of Radiology, University of Molise, Campobasso, Italy.
<sup>11</sup>Department of Radiology, San Paolo Hospital, University of Milan, Milan, Italy.
Conference/Journal: Med Oncol.
Date published: 2017 May
Other:
Volume ID: 34 , Issue ID: 5 , Pages: 96 , Special Notes: doi: 10.1007/s12032-017-0946-x. Epub 2017 Apr 18. , Word Count: 229
The LUMIRA trial evaluated the effectiveness of radiofrequency (RFA) and microwave ablation (MWA) in lung tumours ablation and defining more precisely their fields of application. It is a controlled prospective multi-centre random trial with 1:1 randomization. Fifty-two patients in stage IV disease (15 females and 37 males, mean age 69 y.o., range 40-87) were included. We randomized the patients in two different subgroups: MWA group and RFA group. For each group, we evaluated the technical and clinical success, the overall survival and complication rate. Inter-group difference was compared using Chi-square test or Fisher's exact test for categorical variables and one-way ANOVA test for continuous variables. For RFA group, there was a significant reduction in tumour size only between 6 and 12 months (p value = 0.0014). For MWA group, there was a significant reduction in tumour size between 6 and 12 months (p value = 0.0003) and between pre-therapy and 12 months (p value = 0.0215). There were not significant differences between the two groups in terms of survival time (p value = 0.883), while the pain level in MWA group was significantly less than in RFA group (1.79 < 3.25, p value = 0.0043). In conclusion, our trial confirms RFA and MWA are both excellent choices in terms of efficacy and safety in lung tumour treatments. However, when compared to RFA therapy, MWA produced a less intraprocedural pain and a significant reduction in tumour mass.
KEYWORDS: Ablation treatment; Lung cancer; Microwave; Radiofrequency
PMID: 28417355 DOI: 10.1007/s12032-017-0946-x